# LLY catalysts: ELI LILLY & Co PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/lly/catalysts

> ELI LILLY & Co (LLY) has 195 upcoming catalysts. The next is the LY3537021 primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ELI LILLY & Co |
| Ticker | LLY (NYSE) |
| SEC CIK | 59478 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/lly |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 22, 2016 | [Taltz (ixekizumab) FDA approval](https://sec-api.dev/pdufa/ixekizumab) | LLY |  | completed, approved | "BLA125521 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20160322, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product TALTZ (IXEKIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125521%22)) |
| October 19, 2016 | [Lartruvo (olaratumab) FDA approval](https://sec-api.dev/pdufa/olaratumab) | LLY |  | completed, approved | "BLA761038 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20161019, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product LARTRUVO (OLARATUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761038%22)) |
| September 28, 2017 | [VERZENIO (abemaciclib) FDA approval](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170928, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| February 26, 2018 | [VERZENIO (abemaciclib) FDA approval](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208855 ORIG-1 (Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval): submission_status AP, submission_status_date 20180226, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208855%22)) |
| May 31, 2018 | [OLUMIANT® (baricitinib) FDA approval](https://sec-api.dev/pdufa/baricitinib) | LLY |  | completed, approved | "NDA207924 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180531, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22)) |
| September 27, 2018 | [Emgality (galcanezumab-gnlm) FDA approval](https://sec-api.dev/pdufa/galcanezumab-gnlm) | LLY |  | completed, approved | "BLA761063 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180927, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product EMGALITY (GALCANEZUMAB-GNLM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761063%22)) |
| October 11, 2019 | [Reyvow (lasmiditan succinate) FDA approval](https://sec-api.dev/pdufa/lasmiditan) | LLY |  | completed, approved | "NDA211280 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191011, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product REYVOW (LASMIDITAN SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211280%22)) |
| February 21, 2020 | [Trulicity (dulaglutide) label expansion decision](https://sec-api.dev/pdufa/dulaglutide) | LLY |  | completed, approved | "BLA125469 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20200221, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product TRULICITY (DULAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125469%22)) |
| March 26, 2020 | [Taltz (ixekizumab) label expansion decision](https://sec-api.dev/pdufa/ixekizumab) | LLY |  | completed, approved | "BLA125521 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20200326, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product TALTZ (IXEKIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125521%22)) |
| March 30, 2020 | [VERZENIO (abemaciclib) label expansion decision](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20200330, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| April 20, 2020 | [Cymbalta (duloxetine) label expansion decision](https://sec-api.dev/pdufa/duloxetine) | LLY |  | completed, approved | "NDA021427 SUPPL-52 (Efficacy): submission_status AP, submission_status_date 20200420, review_priority STANDARD; sponsor_name LILLY; product CYMBALTA (DULOXETINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021427%22)) |
| May 8, 2020 | [Retevmo (selpercatinib) FDA approval](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA213246 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200508, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22)) |
| May 29, 2020 | [Taltz (ixekizumab) label expansion decision](https://sec-api.dev/pdufa/ixekizumab) | LLY |  | completed, approved | "BLA125521 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20200529, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product TALTZ (IXEKIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125521%22)) |
| May 29, 2020 | [Cyramza (ramucirumab) label expansion decision](https://sec-api.dev/pdufa/ramucirumab) | LLY |  | completed, approved | "BLA125477 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20200529, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product CYRAMZA (RAMUCIRUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125477%22)) |
| June 15, 2020 | [Lyumjev (insulin lispro-aabc) FDA approval](https://sec-api.dev/pdufa/insulin-lispro-aabc) | LLY |  | completed, approved | "BLA761109 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20200615, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product LYUMJEV (INSULIN LISPRO-AABC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761109%22)) |
| September 3, 2020 | [Trulicity (dulaglutide) label expansion decision](https://sec-api.dev/pdufa/dulaglutide) | LLY |  | completed, approved | "BLA125469 SUPPL-36 (Efficacy): submission_status AP, submission_status_date 20200903, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product TRULICITY (DULAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125469%22)) |
| November 16, 2020 | [Forteo® (teriparatide) label expansion decision](https://sec-api.dev/pdufa/teriparatide) | LLY |  | completed, approved | "NDA021318 SUPPL-54 (Efficacy): submission_status AP, submission_status_date 20201116, review_priority STANDARD; sponsor_name LILLY; product FORTEO (TERIPARATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021318%22)) |
| August 13, 2021 | [Lyumjev (insulin lispro-aabc) label expansion decision](https://sec-api.dev/pdufa/insulin-lispro-aabc) | LLY |  | completed, approved | "BLA761109 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20210813, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product LYUMJEV (INSULIN LISPRO-AABC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761109%22)) |
| October 12, 2021 | [VERZENIO (abemaciclib) label expansion decision](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20211012, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| December 17, 2021 | [Rezvoglar (insulin glargine-aglr) FDA approval](https://sec-api.dev/pdufa/insulin-glargine-aglr) | LLY |  | completed, approved | "BLA761215 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name ELI LILLY CO; product REZVOGLAR (INSULIN GLARGINE-AGLR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761215%22)) |
| December 17, 2021 | [Rezvoglar (insulin glargine-aglr) complete response letter (CRL)](https://sec-api.dev/pdufa/insulin-glargine-aglr) | LLY |  | completed, complete response letter | "We have completed our review of BLA 761215/Original 2, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22Pages%20from%20761215Orig2s000.pdf%22)) |
| May 4, 2022 | [Taltz (ixekizumab) label expansion decision](https://sec-api.dev/pdufa/ixekizumab) | LLY |  | completed, approved | "BLA125521 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20220504, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product TALTZ (IXEKIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125521%22)) |
| May 10, 2022 | [OLUMIANT® (baricitinib) label expansion decision](https://sec-api.dev/pdufa/baricitinib) | LLY |  | completed, approved | "NDA207924 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20220510, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22)) |
| May 13, 2022 | [Zepbound (tirzepatide) FDA approval](https://sec-api.dev/pdufa/tirzepatide) | LLY |  | completed, approved | "Mounjaro \| tirzepatide \| 5/13/2022 \| To improve blood sugar control in diabetes, in addition to diet and exercise Press Release (FDA Archive)Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| June 13, 2022 | [OLUMIANT® (baricitinib) label expansion decision](https://sec-api.dev/pdufa/baricitinib) | LLY |  | completed, approved | "NDA207924 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220613, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22)) |
| August 31, 2022 | [Alimta (pemetrexed) label expansion decision](https://sec-api.dev/pdufa/pemetrexed) | LLY |  | completed, approved | "NDA021462 SUPPL-55 (Efficacy): submission_status AP, submission_status_date 20220831, review_priority STANDARD; sponsor_name LILLY; product ALIMTA (PEMETREXED DISODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021462%22)) |
| September 21, 2022 | [Retevmo (selpercatinib) label expansion decision](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA213246 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220921, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22)) |
| October 14, 2022 | [Lyumjev (insulin lispro-aabc) label expansion decision](https://sec-api.dev/pdufa/insulin-lispro-aabc) | LLY |  | completed, approved | "BLA761109 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20221014, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product LYUMJEV (INSULIN LISPRO-AABC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761109%22)) |
| November 16, 2022 | [Rezvoglar (insulin glargine-aglr) FDA approval](https://sec-api.dev/pdufa/insulin-glargine-aglr) | LLY |  | completed, approved | "BLA761215 ORIG-2 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20221116, review_priority STANDARD; sponsor_name ELI LILLY CO; product REZVOGLAR (INSULIN GLARGINE-AGLR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761215%22)) |
| November 17, 2022 | [Trulicity (dulaglutide) label expansion decision](https://sec-api.dev/pdufa/dulaglutide) | LLY |  | completed, approved | "BLA125469 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20221117, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product TRULICITY (DULAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125469%22)) |
| January 18, 2023 | [Kisunla (donanemab-azbt) complete response letter (CRL)](https://sec-api.dev/pdufa/donanemab-azbt) | LLY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761248_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| January 27, 2023 | [Jaypirca (pirtobrutinib) FDA approval](https://sec-api.dev/pdufa/pirtobrutinib) | LLY |  | completed, approved | "Jaypirca \| pirtobrutinib \| 1/27/2023 \| To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitorDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| March 3, 2023 | [VERZENIO (abemaciclib) label expansion decision](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20230303, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| March 30, 2023 | [Omvoh (mirikizumab-mrkz) complete response letter (CRL)](https://sec-api.dev/pdufa/mirikizumab-mrkz) | LLY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761279_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| September 28, 2023 | [Ebglyss (lebrikizumab-lbkz) complete response letter (CRL)](https://sec-api.dev/pdufa/lebrikizumab-lbkz) | LLY |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761306_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| October 26, 2023 | [Omvoh (mirikizumab-mrkz) FDA approval](https://sec-api.dev/pdufa/mirikizumab-mrkz) | LLY | To treat ulcerative colitis | completed, approved | "Omvoh \| mirikizumab-mrkz \| 10/26/2023 \| To treat ulcerative colitisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| November 8, 2023 | [Zepbound (tirzepatide) FDA approval](https://sec-api.dev/pdufa/tirzepatide) | LLY |  | completed, approved | "NDA217806 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20231108, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22)) |
| December 1, 2023 | [Jaypirca (pirtobrutinib) label expansion decision](https://sec-api.dev/pdufa/pirtobrutinib) | LLY |  | completed, approved | "NDA216059 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20231201, review_priority PRIORITY; sponsor_name LOXO ONCOL; product JAYPIRCA (PIRTOBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216059%22)) |
| April 10, 2024 | [Retevmo (selpercatinib) FDA approval](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA218160 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240410, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218160%22)) |
| May 29, 2024 | [Retevmo (selpercatinib) label expansion decision](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA213246 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20240529, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22)) |
| June 12, 2024 | [Retevmo (selpercatinib) label expansion decision](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA213246 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20240612, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22)) |
| July 2, 2024 | [Kisunla (donanemab-azbt) FDA approval](https://sec-api.dev/pdufa/donanemab-azbt) | LLY | To treat Alzheimer’s disease | completed, approved | "Kisunla \| donanemab-azbt \| 7/2/2024 \| To treat Alzheimer’s diseaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| September 13, 2024 | [Ebglyss (lebrikizumab-lbkz) FDA approval](https://sec-api.dev/pdufa/lebrikizumab-lbkz) | LLY | To treat moderate-to-severe atopic dermatitis | completed, approved | "Ebglyss \| lebrikizumab-lbkz \| 9/13/2024 \| To treat moderate-to-severe atopic dermatitisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| September 27, 2024 | [Retevmo (selpercatinib) label expansion decision](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA213246 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20240927, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22)) |
| October 18, 2024 | [Zepbound (tirzepatide) label expansion decision](https://sec-api.dev/pdufa/tirzepatide) | LLY |  | completed, approved | "NDA217806 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20241018, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22)) |
| November 13, 2024 | [VERZENIO (abemaciclib) label expansion decision](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20241113, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| December 20, 2024 | [Zepbound (tirzepatide) label expansion decision](https://sec-api.dev/pdufa/tirzepatide) | LLY |  | completed, approved | "NDA217806 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22)) |
| January 15, 2025 | [Omvoh (mirikizumab-mrkz) label expansion decision](https://sec-api.dev/pdufa/mirikizumab-mrkz) | LLY |  | completed, approved | "BLA761279 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250115, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OMVOH (MIRIKIZUMAB-MRKZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761279%22)) |
| January 27, 2025 | [Cyramza (ramucirumab) label expansion decision](https://sec-api.dev/pdufa/ramucirumab) | LLY |  | completed, approved | "BLA125477 SUPPL-48 (Efficacy): submission_status AP, submission_status_date 20250127, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product CYRAMZA (RAMUCIRUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125477%22)) |
| February 6, 2025 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports full Q4 2024 financial results and provides 2025 guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947825000037/q424lillysalesandearningsp.htm)) |
| April 7, 2025 | [Cyramza (ramucirumab) label expansion decision](https://sec-api.dev/pdufa/ramucirumab) | LLY |  | completed, approved | "BLA125477 SUPPL-49 (Efficacy): submission_status AP, submission_status_date 20250407, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product CYRAMZA (RAMUCIRUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125477%22)) |
| May 1, 2025 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports first-quarter 2025 financial results and highlights pipeline momentum" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/q125lillysalesandearningsp.htm)) |
| May 30, 2025 | [Eloralintide primary completion](https://sec-api.dev/pdufa/eloralintide) | LLY | Obesity; Overweight | completed | "NCT06230523 (A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06230523)) |
| June 5, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06010004 (A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06010004)) |
| June 11, 2025 | [Mazisotine primary completion](https://sec-api.dev/pdufa/mazisotine) | LLY | Diabetic Peripheral Neuropathy | completed | "NCT06074562 (A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06074562)) |
| June 12, 2025 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 2 Diabetes Mellitus | completed | "NCT04255433 (A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04255433)) |
| June 19, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity | completed | "NCT05931380 (A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05931380)) |
| July 1, 2025 | [Kisunla (donanemab-azbt) label expansion decision](https://sec-api.dev/pdufa/donanemab-azbt) | LLY |  | completed, approved | "BLA761248 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20250701, review_priority PRIORITY; sponsor_name ELI LILLY CO; product KISUNLA (DONANEMAB-AZBT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761248%22)) |
| July 11, 2025 | [Jaypirca (pirtobrutinib) primary completion](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | completed | "NCT05023980 (A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-11 (ACTUAL); Lead Sponsor Loxo Oncology, Inc.; Results First Posted 2026-09-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05023980)) |
| July 25, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Overweight or Obesity | completed | "NCT05869903 (A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-08-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05869903)) |
| July 29, 2025 | [LY3549492 primary completion](https://sec-api.dev/pdufa/ly3549492) | LLY | Obesity; Overweight; Type 2 Diabetes | withdrawn | "NCT07030868 (A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-08-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07030868)) |
| August 7, 2025 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports second-quarter 2025 financial results and raises guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947825000202/q225lillysalesandearningsp.htm)) |
| August 8, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Type 2 Diabetes | completed | "NCT05872620 (A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-08 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05872620)) |
| August 14, 2025 | [LY3549492 primary completion](https://sec-api.dev/pdufa/ly3549492) | LLY | Healthy | withdrawn | "NCT07085468 (A Study of LY3549492 in Healthy Weight Adult Participants): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07085468)) |
| August 22, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06045221 (A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045221)) |
| September 15, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06109311 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-15 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109311)) |
| September 25, 2025 | [Inluriyo™ (imlunestrant) FDA approval](https://sec-api.dev/pdufa/imlunestrant) | LLY |  | completed, approved | "Inluriyo \| imlunestrant \| 9/25/2025 \| To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| September 25, 2025 | [Lebrikizumab primary completion](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis | completed | "NCT06280716 (A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280716)) |
| September 26, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06192108 (A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-26 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06192108)) |
| September 30, 2025 | [Eltrekibart primary completion](https://sec-api.dev/pdufa/eltrekibart) | LLY | Hidradenitis Suppurativa | completed | "NCT06046729 (A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06046729)) |
| October 1, 2025 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Overweight or Obesity; CKD; Type 2 Diabetes | completed | "NCT05936151 (A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-11-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05936151)) |
| October 18, 2025 | [LY3541860 primary completion](https://sec-api.dev/pdufa/ly3541860) | LLY | Multiple Sclerosis | withdrawn | "NCT06220669 (A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-18 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06220669)) |
| October 30, 2025 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947825000251/q325lillysalesandearningsp.htm)) |
| November 10, 2025 | [LY3541860 primary completion](https://sec-api.dev/pdufa/ly3541860) | LLY | Rheumatoid Arthritis | withdrawn | "NCT06859294 (A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-11-10 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06859294)) |
| November 12, 2025 | [Reyvow (lasmiditan succinate) primary completion](https://sec-api.dev/pdufa/lasmiditan) | LLY | Migraine | withdrawn | "NCT04396236 (A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04396236)) |
| November 14, 2025 | [Galcanezumab primary completion](https://sec-api.dev/pdufa/galcanezumab) | LLY | Episodic Migraine | completed | "NCT03432286 (A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03432286)) |
| November 14, 2025 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight; Osteo Arthritis Knee | completed | "NCT05931367 (A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05931367)) |
| November 18, 2025 | [Taltz (ixekizumab) primary completion](https://sec-api.dev/pdufa/ixekizumab) | LLY | Psoriatic Arthritis; Obesity | completed | "NCT06588296 (Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-18 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588296)) |
| November 20, 2025 | [Retevmo (selpercatinib) label expansion decision](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA213246 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20251120, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22)) |
| November 21, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | completed | "NCT06584916 (A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06584916)) |
| December 2, 2025 | [Jaypirca (pirtobrutinib) label expansion decision](https://sec-api.dev/pdufa/pirtobrutinib) | LLY |  | completed, approved | "NDA216059 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20251202, review_priority STANDARD; sponsor_name LOXO ONCOL; product JAYPIRCA (PIRTOBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216059%22)) |
| December 4, 2025 | [Reyvow (lasmiditan succinate) primary completion](https://sec-api.dev/pdufa/lasmiditan) | LLY | Migraine | withdrawn | "NCT04396574 (A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-04 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04396574)) |
| December 8, 2025 | [LY3871801 primary completion](https://sec-api.dev/pdufa/ly3871801) | LLY | Rheumatoid Arthritis | completed | "NCT05848258 (An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-08 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05848258)) |
| December 10, 2025 | [Galcanezumab primary completion](https://sec-api.dev/pdufa/galcanezumab) | LLY | Chronic Migraine | completed | "NCT04616326 (A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-10 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04616326)) |
| December 15, 2025 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | completed | "NCT06373146 (A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06373146)) |
| December 19, 2025 | [Zepbound (tirzepatide) label expansion decision](https://sec-api.dev/pdufa/tirzepatide) | LLY |  | completed, approved | "NDA215866 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20251219, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product MOUNJARO (TIRZEPATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215866%22)) |
| January 7, 2026 | [LY3549492 primary completion](https://sec-api.dev/pdufa/ly3549492) | LLY | Obesity; Overweight | completed | "NCT06683508 (A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-07 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06683508)) |
| January 8, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 2 Diabetes; Obesity | completed | "NCT06037252 (A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-08 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06037252)) |
| January 8, 2026 | [Taltz (ixekizumab) primary completion](https://sec-api.dev/pdufa/ixekizumab) | LLY | Psoriasis; Obesity | completed | "NCT06588283 (Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-08 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588283)) |
| January 12, 2026 | [Retevmo (selpercatinib) primary completion](https://sec-api.dev/pdufa/selpercatinib) | LLY | Carcinoma, Non-Small-Cell Lung | completed | "NCT04819100 (A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04819100)) |
| January 12, 2026 | [LY3848575 primary completion](https://sec-api.dev/pdufa/ly3848575) | LLY | Neuropathic Pain; Distal Sensory Polyneuropathy | completed | "NCT06568042 (Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568042)) |
| January 14, 2026 | [Lebrikizumab primary completion](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis; Eczema | completed | "NCT05559359 (A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05559359)) |
| January 16, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | completed | "NCT06643728 (A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-16 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643728)) |
| January 20, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Overweight; Obesity | completed | "NCT06047548 (A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06047548)) |
| January 22, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Diabetes Type 2 | completed | "NCT06354660 (Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-22 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06354660)) |
| February 4, 2026 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/q425lillysalesandearningsp.htm)) |
| March 4, 2026 | [Mirikizumab primary completion](https://sec-api.dev/pdufa/mirikizumab) | LLY | Ulcerative Colitis | completed | "NCT03519945 (A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03519945)) |
| March 16, 2026 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes; Obesity; Overweight or Obesity | completed | "NCT05803421 (A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-16 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05803421)) |
| March 19, 2026 | [Mazdutide primary completion](https://sec-api.dev/pdufa/mazdutide) | LLY | Alcohol Use Disorder | completed | "NCT06817356 (A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-19 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06817356)) |
| April 1, 2026 | [Foundayo (orforglipron calcium) FDA approval](https://sec-api.dev/pdufa/orforglipron) | LLY |  | completed, approved | "Foundayo \| orforglipron \| 4/1/2026 \| To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| April 6, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight; Osteoarthritis, Knee | completed | "NCT05929066 (A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-06 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05929066)) |
| April 16, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Cardiovascular Diseases | completed | "NCT05882045 (A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-16 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882045)) |
| April 30, 2026 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/q126lillysalesandearningsp.htm)) |
| May 1, 2026 | [Mirikizumab iv primary completion](https://sec-api.dev/pdufa/mirikizumab-iv) | LLY | Ulcerative Colitis | completed | "NCT05784246 (A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05784246)) |
| May 1, 2026 | [Mevidalen primary completion](https://sec-api.dev/pdufa/mevidalen) | LLY | Alzheimer Disease | completed | "NCT06538116 (A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06538116)) |
| May 13, 2026 | [Lebrikizumab primary completion](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Hand and Foot Dermatitis | completed | "NCT06921759 (A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06921759)) |
| June 2, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | completed | "NCT06075667 (A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-02 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06075667)) |
| June 9, 2026 | [Ebglyss (lebrikizumab-lbkz) label expansion decision](https://sec-api.dev/pdufa/lebrikizumab-lbkz) | LLY |  | completed, approved | "BLA761306 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260609, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product EBGLYSS (LEBRIKIZUMAB-LBKZ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761306%22)) |
| June 16, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Type 2 Diabetes; Obesity; Overweight | completed | "NCT05929079 (A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-16 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05929079)) |
| June 24, 2026 | [Eloralintide topline data readout](https://sec-api.dev/pdufa/eloralintide) | LLY | Obesity; Overweight | completed | "NCT06230523 (A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06230523?tab=results)) |
| June 30, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06010004 (A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06010004?tab=results)) |
| July 1, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | completed | "NCT06603571 (A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-01 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06603571)) |
| July 6, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Overweight; Obesity; Chronic Kidney Disease | completed | "NCT05536804 (A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-06 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05536804)) |
| July 8, 2026 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 2 Diabetes Mellitus | completed | "NCT04255433 (A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04255433?tab=results)) |
| July 13, 2026 | [VERZENIO (abemaciclib) label expansion decision](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20260713, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| July 14, 2026 | [Retevmo (selpercatinib) label expansion decision](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA213246 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260714, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22)) |
| July 20, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity | completed | "NCT05931380 (A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05931380?tab=results)) |
| July 21, 2026 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | OSA; Overweight or Obesity | completed | "NCT06649045 (A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06649045)) |
| July 30, 2026 | [Mazisotine topline data readout](https://sec-api.dev/pdufa/mazisotine) | LLY | Diabetic Peripheral Neuropathy | completed | "NCT06074562 (A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06074562?tab=results)) |
| August 3, 2026 | [Eltrekibart primary completion](https://sec-api.dev/pdufa/eltrekibart) | LLY | Ulcerative Colitis; Ulcerative Colitis Chronic | completed | "NCT06598943 (A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06598943)) |
| Aug to Nov 2026 | [Eltrekibart topline data readout](https://sec-api.dev/pdufa/eltrekibart) | LLY | Ulcerative Colitis; Ulcerative Colitis Chronic | scheduled | "NCT06598943 (A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06598943)) |
| August 5, 2026 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm)) |
| August 14, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Overweight or Obesity | completed | "NCT05869903 (A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-08-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05869903?tab=results)) |
| August 26, 2026 | [Zepbound (tirzepatide) label expansion decision](https://sec-api.dev/pdufa/tirzepatide) | LLY |  | completed, approved | "NDA217806 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20260826, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22)) |
| August 27, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Diabetes Mellitus, Type 2 | completed | "NCT06260722 (Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260722)) |
| Aug to Nov 2026 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT06260722 (Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260722)) |
| September 4, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Type 2 Diabetes | completed | "NCT05872620 (A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-08 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05872620?tab=results)) |
| September 15, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06045221 (A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045221?tab=results)) |
| September 18, 2026 | [VERZENIO (abemaciclib) label expansion decision](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20260918, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| September 18, 2026 | [Inluriyo™ (imlunestrant) label expansion decision](https://sec-api.dev/pdufa/imlunestrant) | LLY |  | completed, approved | "NDA218881 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20260918, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product INLURIYO (IMLUNESTRANT TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218881%22)) |
| September 23, 2026 | [Onswik (insulin efsitora alfa-gobe) FDA approval](https://sec-api.dev/pdufa/insulin-efsitora-alfa-gobe) | LLY |  | completed, approved | "Onswik \| insulin efsitora alfa-gobe \| 9/23/2026 \| To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 25, 2026 | [OLUMIANT® (baricitinib) label expansion decision](https://sec-api.dev/pdufa/baricitinib) | LLY |  | completed, approved | "NDA207924 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260925, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22)) |
| September 25, 2026 | [Jaypirca (pirtobrutinib) topline data readout](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | completed | "NCT05023980 (A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-11 (ACTUAL); Lead Sponsor Loxo Oncology, Inc.; Results First Posted 2026-09-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05023980?tab=results)) |
| October 2026 | [OLUMIANT® (baricitinib) primary completion](https://sec-api.dev/pdufa/baricitinib) | LLY | Systemic Juvenile Idiopathic Arthritis | delayed | "NCT04088396 (A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04088396)) |
| Oct 2026 to Jan 2027 | [OLUMIANT® (baricitinib) topline data readout](https://sec-api.dev/pdufa/baricitinib) | LLY | Systemic Juvenile Idiopathic Arthritis | scheduled | "NCT04088396 (A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04088396)) |
| October 2026 | [Jaypirca (pirtobrutinib) primary completion](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | delayed | "NCT04965493 (A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04965493)) |
| Oct 2026 to Jan 2027 | [Jaypirca (pirtobrutinib) topline data readout](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT04965493 (A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04965493)) |
| October 1, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06109311 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-15 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109311?tab=results)) |
| October 2, 2026 | [Jaypirca (pirtobrutinib) label expansion decision](https://sec-api.dev/pdufa/pirtobrutinib) | LLY |  | completed, approved | "NDA216059 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20261002, review_priority STANDARD; sponsor_name LOXO ONCOL; product JAYPIRCA (PIRTOBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216059%22)) |
| October 9, 2026 | [OLUMIANT® (baricitinib) label expansion decision](https://sec-api.dev/pdufa/baricitinib) | LLY |  | completed, approved | "NDA207924 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20261009, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22)) |
| October 16, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06192108 (A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-26 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06192108?tab=results)) |
| October 16, 2026 | [Lebrikizumab topline data readout](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis | completed | "NCT06280716 (A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280716?tab=results)) |
| October 22, 2026 | [LY3650150 primary completion](https://sec-api.dev/pdufa/ly3650150) | LLY | Perennial Allergic Rhinitis (PAR) | completed | "NCT06339008 (A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-22 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06339008)) |
| Oct 2026 to Jan 2027 | [LY3650150 topline data readout](https://sec-api.dev/pdufa/ly3650150) | LLY | Perennial Allergic Rhinitis (PAR) | scheduled | "NCT06339008 (A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-22 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06339008)) |
| October 26, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Type 2 Diabetes | completed | "NCT06297603 (Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06297603)) |
| Oct 2026 to Jan 2027 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Type 2 Diabetes | scheduled | "NCT06297603 (Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06297603)) |
| October 29, 2026 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/q326lillysalesandearningsp.htm)) |
| November 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT06662383 (A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06662383)) |
| Nov 2026 to Feb 2027 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT06662383 (A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06662383)) |
| November 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 1 Diabetes; Obesity; Overweight | scheduled | "NCT06914895 (A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914895)) |
| Nov 2026 to Feb 2027 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 1 Diabetes; Obesity; Overweight | scheduled | "NCT06914895 (A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914895)) |
| November 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 1 Diabetes; Obesity; Overweight | scheduled | "NCT06962280 (A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06962280)) |
| Nov 2026 to Feb 2027 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 1 Diabetes; Obesity; Overweight | scheduled | "NCT06962280 (A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06962280)) |
| November 2026 | [LY3938577 primary completion](https://sec-api.dev/pdufa/ly3938577) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT07215312 (A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215312)) |
| Nov 2026 to Feb 2027 | [LY3938577 topline data readout](https://sec-api.dev/pdufa/ly3938577) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT07215312 (A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215312)) |
| November 2026 | [LY4515100 primary completion](https://sec-api.dev/pdufa/ly4515100) | LLY | Acute Pain; Molar; Molar, Third | scheduled | "NCT07511816 (A Study of LY4515100 in Participants With Pain Following Third Molar Removal): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07511816)) |
| Nov 2026 to Feb 2027 | [LY4515100 topline data readout](https://sec-api.dev/pdufa/ly4515100) | LLY | Acute Pain; Molar; Molar, Third | scheduled | "NCT07511816 (A Study of LY4515100 in Participants With Pain Following Third Molar Removal): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07511816)) |
| November 9, 2026 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Overweight or Obesity; CKD; Type 2 Diabetes | completed | "NCT05936151 (A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-11-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05936151?tab=results)) |
| December 2026 | [LY3537021 primary completion](https://sec-api.dev/pdufa/ly3537021) | LLY | Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions | scheduled | "NCT07169851 (A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07169851)) |
| Dec 2026 to Mar 2027 | [LY3537021 topline data readout](https://sec-api.dev/pdufa/ly3537021) | LLY | Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions | scheduled | "NCT07169851 (A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07169851)) |
| Q1 2027 | [Retatrutide NDA/BLA submission](https://sec-api.dev/pdufa/retatrutide) | LLY |  | scheduled | "The clinical data package is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm)) |
| February 2027 | [VERZENIO (abemaciclib) primary completion](https://sec-api.dev/pdufa/abemaciclib) | LLY | Glioma | scheduled | "NCT06413706 (A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06413706)) |
| Feb to May 2027 | [VERZENIO (abemaciclib) topline data readout](https://sec-api.dev/pdufa/abemaciclib) | LLY | Glioma | scheduled | "NCT06413706 (A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06413706)) |
| February 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | scheduled | "NCT06672549 (A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06672549)) |
| Feb to May 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | scheduled | "NCT06672549 (A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06672549)) |
| February 2027 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Smoking | scheduled | "NCT07223840 (A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223840)) |
| Feb to May 2027 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Smoking | scheduled | "NCT07223840 (A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223840)) |
| March 2027 | [Macupatide primary completion](https://sec-api.dev/pdufa/macupatide) | LLY | Obesity; Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07215559 (A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215559)) |
| Mar to Jun 2027 | [Macupatide topline data readout](https://sec-api.dev/pdufa/macupatide) | LLY | Obesity; Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07215559 (A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215559)) |
| March 2027 | [Solbinsiran primary completion](https://sec-api.dev/pdufa/solbinsiran) | LLY | Severe Hypertriglyceridemia | scheduled | "NCT07269210 (A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07269210)) |
| Mar to Jun 2027 | [Solbinsiran topline data readout](https://sec-api.dev/pdufa/solbinsiran) | LLY | Severe Hypertriglyceridemia | scheduled | "NCT07269210 (A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07269210)) |
| April 2027 | [Ly3016859 isa primary completion](https://sec-api.dev/pdufa/ly3016859-isa) | LLY | Osteoarthritis, Knee; Diabetic Neuropathic Pain; Chronic Low-back Pain | scheduled | "NCT05986292 (A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05986292)) |
| Apr to Jul 2027 | [Ly3016859 isa topline data readout](https://sec-api.dev/pdufa/ly3016859-isa) | LLY | Osteoarthritis, Knee; Diabetic Neuropathic Pain; Chronic Low-back Pain | scheduled | "NCT05986292 (A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05986292)) |
| April 2027 | [LY4065967 primary completion](https://sec-api.dev/pdufa/ly4065967) | LLY | Chronic Pain; Low Back Pain | scheduled | "NCT07641504 (A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07641504)) |
| Apr to Jul 2027 | [LY4065967 topline data readout](https://sec-api.dev/pdufa/ly4065967) | LLY | Chronic Pain; Low Back Pain | scheduled | "NCT07641504 (A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07641504)) |
| April 2027 | [LY4065967 primary completion](https://sec-api.dev/pdufa/ly4065967) | LLY | Osteoarthritis, Knee; Chronic Pain | scheduled | "NCT07641517 (A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07641517)) |
| Apr to Jul 2027 | [LY4065967 topline data readout](https://sec-api.dev/pdufa/ly4065967) | LLY | Osteoarthritis, Knee; Chronic Pain | scheduled | "NCT07641517 (A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07641517)) |
| May 2027 | [Cyramza (ramucirumab) primary completion](https://sec-api.dev/pdufa/ramucirumab) | LLY | Neoplasms; Child; Adolescent | scheduled | "NCT05999994 (A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05999994)) |
| May to Aug 2027 | [Cyramza (ramucirumab) topline data readout](https://sec-api.dev/pdufa/ramucirumab) | LLY | Neoplasms; Child; Adolescent | scheduled | "NCT05999994 (A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05999994)) |
| May 2027 | [LY3650150 primary completion](https://sec-api.dev/pdufa/ly3650150) | LLY | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | scheduled | "NCT06338995 (A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06338995)) |
| May to Aug 2027 | [LY3650150 topline data readout](https://sec-api.dev/pdufa/ly3650150) | LLY | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | scheduled | "NCT06338995 (A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06338995)) |
| May 2027 | [LY3457263 primary completion](https://sec-api.dev/pdufa/ly3457263) | LLY | Type 2 Diabetes | scheduled | "NCT06897475 (A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897475)) |
| May to Aug 2027 | [LY3457263 topline data readout](https://sec-api.dev/pdufa/ly3457263) | LLY | Type 2 Diabetes | scheduled | "NCT06897475 (A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897475)) |
| May 2027 | [Zotemtegrast primary completion](https://sec-api.dev/pdufa/zotemtegrast) | LLY | Ulcerative Colitis | scheduled | "NCT07186101 (LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07186101)) |
| May to Aug 2027 | [Zotemtegrast topline data readout](https://sec-api.dev/pdufa/zotemtegrast) | LLY | Ulcerative Colitis | scheduled | "NCT07186101 (LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07186101)) |
| May 2027 | [LY4005130 primary completion](https://sec-api.dev/pdufa/ly4005130) | LLY | Vitiligo; Non-Segmental Vitiligo (NSV) | scheduled | "NCT07533019 (A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533019)) |
| May to Aug 2027 | [LY4005130 topline data readout](https://sec-api.dev/pdufa/ly4005130) | LLY | Vitiligo; Non-Segmental Vitiligo (NSV) | scheduled | "NCT07533019 (A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533019)) |
| May 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders | scheduled | "NCT07613307 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07613307)) |
| May to Aug 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders | scheduled | "NCT07613307 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07613307)) |
| May 2027 | [Clazakizumab primary completion](https://sec-api.dev/pdufa/clazakizumab) | LLY | Atherosclerosis; Cardiovascular Disease; Obesity | scheduled | "NCT07783802 (A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783802)) |
| May to Aug 2027 | [Clazakizumab topline data readout](https://sec-api.dev/pdufa/clazakizumab) | LLY | Atherosclerosis; Cardiovascular Disease; Obesity | scheduled | "NCT07783802 (A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783802)) |
| June 2027 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight | scheduled | "NCT07232719 (A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07232719)) |
| Jun to Sep 2027 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight | scheduled | "NCT07232719 (A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07232719)) |
| June 2027 | [LY4395089 primary completion](https://sec-api.dev/pdufa/ly4395089) | LLY | Colitis, Ulcerative; Crohn Disease | scheduled | "NCT07483073 (A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07483073)) |
| Jun to Sep 2027 | [LY4395089 topline data readout](https://sec-api.dev/pdufa/ly4395089) | LLY | Colitis, Ulcerative; Crohn Disease | scheduled | "NCT07483073 (A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07483073)) |
| June 2027 | [LY4395089 primary completion](https://sec-api.dev/pdufa/ly4395089) | LLY | Crohn Disease | scheduled | "NCT07483099 (A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07483099)) |
| Jun to Sep 2027 | [LY4395089 topline data readout](https://sec-api.dev/pdufa/ly4395089) | LLY | Crohn Disease | scheduled | "NCT07483099 (A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07483099)) |
| June 2027 | [LY4005130 primary completion](https://sec-api.dev/pdufa/ly4005130) | LLY | Alopecia Areata | scheduled | "NCT07533006 (A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533006)) |
| Jun to Sep 2027 | [LY4005130 topline data readout](https://sec-api.dev/pdufa/ly4005130) | LLY | Alopecia Areata | scheduled | "NCT07533006 (A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533006)) |
| July 2027 | [LY4065967 primary completion](https://sec-api.dev/pdufa/ly4065967) | LLY | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT07285018 (A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285018)) |
| Jul to Oct 2027 | [LY4065967 topline data readout](https://sec-api.dev/pdufa/ly4065967) | LLY | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT07285018 (A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285018)) |
| July 2027 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Irritable Bowel Syndrome; Constipation | scheduled | "NCT07545772 (A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07545772)) |
| Jul to Oct 2027 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Irritable Bowel Syndrome; Constipation | scheduled | "NCT07545772 (A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07545772)) |
| August 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | scheduled | "NCT06972459 (A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972459)) |
| Aug to Nov 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | scheduled | "NCT06972459 (A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972459)) |
| August 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Type 2 Diabetes | scheduled | "NCT06972472 (A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972472)) |
| Aug to Nov 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Type 2 Diabetes | scheduled | "NCT06972472 (A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972472)) |
| August 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Type 2 Diabetes | scheduled | "NCT06993792 (A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06993792)) |
| Aug to Nov 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Type 2 Diabetes | scheduled | "NCT06993792 (A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06993792)) |
| September 2027 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | scheduled | "NCT06143956 (A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06143956)) |
| Sep to Dec 2027 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | scheduled | "NCT06143956 (A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06143956)) |
| September 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension | scheduled | "NCT06948422 (A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06948422)) |
| Sep to Dec 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension | scheduled | "NCT06948422 (A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06948422)) |
| September 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension; Overweight or Obesity | scheduled | "NCT06948435 (A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06948435)) |
| Sep to Dec 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension; Overweight or Obesity | scheduled | "NCT06948435 (A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06948435)) |
| September 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension | scheduled | "NCT06952530 (A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06952530)) |
| Sep to Dec 2027 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Hypertension | scheduled | "NCT06952530 (A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06952530)) |
| September 2027 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight; Chronic Low Back Pain (CLBP) | scheduled | "NCT07035093 (A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07035093)) |
| Sep to Dec 2027 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight; Chronic Low Back Pain (CLBP) | scheduled | "NCT07035093 (A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07035093)) |
| September 2027 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Irritable Bowel Syndrome; Diarrhea | scheduled | "NCT07545759 (A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07545759)) |
| Sep to Dec 2027 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Irritable Bowel Syndrome; Diarrhea | scheduled | "NCT07545759 (A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07545759)) |
| September 2027 | [Macupatide primary completion](https://sec-api.dev/pdufa/macupatide) | LLY | Overweight; Obesity | scheduled | "NCT07589608 (A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07589608)) |
| Sep to Dec 2027 | [Macupatide topline data readout](https://sec-api.dev/pdufa/macupatide) | LLY | Overweight; Obesity | scheduled | "NCT07589608 (A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07589608)) |
| October 2027 | [Jaypirca (pirtobrutinib) primary completion](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell | scheduled | "NCT05254743 (A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05254743)) |
| Oct 2027 to Jan 2028 | [Jaypirca (pirtobrutinib) topline data readout](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell | scheduled | "NCT05254743 (A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05254743)) |
| October 2027 | [Inluriyo™ (imlunestrant) primary completion](https://sec-api.dev/pdufa/imlunestrant) | LLY | Breast Neoplasms | scheduled | "NCT05514054 (A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05514054)) |
| Oct 2027 to Jan 2028 | [Inluriyo™ (imlunestrant) topline data readout](https://sec-api.dev/pdufa/imlunestrant) | LLY | Breast Neoplasms | scheduled | "NCT05514054 (A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05514054)) |
| October 2027 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | scheduled | "NCT05556512 (A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05556512)) |
| Oct 2027 to Jan 2028 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | scheduled | "NCT05556512 (A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05556512)) |
| October 2027 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Weight Gain | scheduled | "NCT06439277 (A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06439277)) |
| Oct 2027 to Jan 2028 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Weight Gain | scheduled | "NCT06439277 (A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06439277)) |
| November 2027 | [Jaypirca (pirtobrutinib) primary completion](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Lymphoma, Mantle-Cell | scheduled | "NCT04662255 (Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04662255)) |
| Nov 2027 to Feb 2028 | [Jaypirca (pirtobrutinib) topline data readout](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Lymphoma, Mantle-Cell | scheduled | "NCT04662255 (Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04662255)) |
| November 2027 | [Donanemab primary completion](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease | scheduled | "NCT05026866 (A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05026866)) |
| Nov 2027 to Feb 2028 | [Donanemab topline data readout](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease | scheduled | "NCT05026866 (A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05026866)) |
| November 2027 | [Alimta (pemetrexed) primary completion](https://sec-api.dev/pdufa/pemetrexed) | LLY | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | scheduled | "NCT06119581 (A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06119581)) |
| Nov 2027 to Feb 2028 | [Alimta (pemetrexed) topline data readout](https://sec-api.dev/pdufa/pemetrexed) | LLY | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | scheduled | "NCT06119581 (A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06119581)) |
| November 2027 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Bipolar Disorder | scheduled | "NCT07286175 (A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286175)) |
| Nov 2027 to Feb 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Bipolar Disorder | scheduled | "NCT07286175 (A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286175)) |
| November 2027 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Schizophrenia | scheduled | "NCT07410507 (A Study of Brenipatide in Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07410507)) |
| Nov 2027 to Feb 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Schizophrenia | scheduled | "NCT07410507 (A Study of Brenipatide in Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07410507)) |
| December 2027 | [Mirikizumab primary completion](https://sec-api.dev/pdufa/mirikizumab) | LLY | Crohn's Disease | scheduled | "NCT05509777 (A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05509777)) |
| Dec 2027 to Mar 2028 | [Mirikizumab topline data readout](https://sec-api.dev/pdufa/mirikizumab) | LLY | Crohn's Disease | scheduled | "NCT05509777 (A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05509777)) |
| December 2027 | [Lebrikizumab primary completion](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis; Eczema | scheduled | "NCT05735483 (A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05735483)) |
| Dec 2027 to Mar 2028 | [Lebrikizumab topline data readout](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis; Eczema | scheduled | "NCT05735483 (A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05735483)) |
| December 2027 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | scheduled | "NCT06672939 (A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06672939)) |
| Dec 2027 to Mar 2028 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | scheduled | "NCT06672939 (A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06672939)) |
| December 2027 | [Trulicity (dulaglutide) primary completion](https://sec-api.dev/pdufa/dulaglutide) | LLY | Type 2 Diabetes | scheduled | "NCT06739122 (A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06739122)) |
| Dec 2027 to Mar 2028 | [Trulicity (dulaglutide) topline data readout](https://sec-api.dev/pdufa/dulaglutide) | LLY | Type 2 Diabetes | scheduled | "NCT06739122 (A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06739122)) |
| December 2027 | [VERZENIO (abemaciclib) primary completion](https://sec-api.dev/pdufa/abemaciclib) | LLY | Breast Neoplasms | scheduled | "NCT07935317 (A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07935317)) |
| Dec 2027 to Mar 2028 | [VERZENIO (abemaciclib) topline data readout](https://sec-api.dev/pdufa/abemaciclib) | LLY | Breast Neoplasms | scheduled | "NCT07935317 (A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07935317)) |
| January 2028 | [Eloralintide primary completion](https://sec-api.dev/pdufa/eloralintide) | LLY | Overweight; Obesity | scheduled | "NCT07282600 (A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282600)) |
| Jan to Apr 2028 | [Eloralintide topline data readout](https://sec-api.dev/pdufa/eloralintide) | LLY | Overweight; Obesity | scheduled | "NCT07282600 (A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282600)) |
| January 2028 | [LY4086940 primary completion](https://sec-api.dev/pdufa/ly4086940) | LLY | Obesity; Overweight | scheduled | "NCT07890376 (A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890376)) |
| Jan to Apr 2028 | [LY4086940 topline data readout](https://sec-api.dev/pdufa/ly4086940) | LLY | Obesity; Overweight | scheduled | "NCT07890376 (A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890376)) |
| February 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Depressive Disorder, Major | scheduled | "NCT07412756 (A Study of Brenipatide in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412756)) |
| Feb to May 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Depressive Disorder, Major | scheduled | "NCT07412756 (A Study of Brenipatide in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412756)) |
| March 2028 | [OLUMIANT® (baricitinib) primary completion](https://sec-api.dev/pdufa/baricitinib) | LLY | Areata Alopecia; Alopecia; Hypotrichosis | scheduled | "NCT05723198 (A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05723198)) |
| Mar to Jun 2028 | [OLUMIANT® (baricitinib) topline data readout](https://sec-api.dev/pdufa/baricitinib) | LLY | Areata Alopecia; Alopecia; Hypotrichosis | scheduled | "NCT05723198 (A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05723198)) |
| March 2028 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Urinary Incontinence,Stress | scheduled | "NCT07202884 (A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07202884)) |
| Mar to Jun 2028 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Urinary Incontinence,Stress | scheduled | "NCT07202884 (A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07202884)) |
| March 2028 | [Eloralintide primary completion](https://sec-api.dev/pdufa/eloralintide) | LLY | Obesity; Overweight | scheduled | "NCT07321886 (A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07321886)) |
| Mar to Jun 2028 | [Eloralintide topline data readout](https://sec-api.dev/pdufa/eloralintide) | LLY | Obesity; Overweight | scheduled | "NCT07321886 (A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07321886)) |
| March 2028 | [Eloralintide primary completion](https://sec-api.dev/pdufa/eloralintide) | LLY | Osteoarthritis; Overweight or Obesity | scheduled | "NCT07353931 (Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07353931)) |
| Mar to Jun 2028 | [Eloralintide topline data readout](https://sec-api.dev/pdufa/eloralintide) | LLY | Osteoarthritis; Overweight or Obesity | scheduled | "NCT07353931 (Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07353931)) |
| March 2028 | [Eloralintide primary completion](https://sec-api.dev/pdufa/eloralintide) | LLY | Sleep Apnea, Obstructive; Obesity; Overweight | scheduled | "NCT07369011 (A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07369011)) |
| Mar to Jun 2028 | [Eloralintide topline data readout](https://sec-api.dev/pdufa/eloralintide) | LLY | Sleep Apnea, Obstructive; Obesity; Overweight | scheduled | "NCT07369011 (A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07369011)) |
| March 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Opioid Use Disorder | scheduled | "NCT07420283 (A Study of Brenipatide in Participants With Opioid Use Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07420283)) |
| Mar to Jun 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Opioid Use Disorder | scheduled | "NCT07420283 (A Study of Brenipatide in Participants With Opioid Use Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07420283)) |
| March 2028 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | scheduled | "NCT07790861 (A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07790861)) |
| Mar to Jun 2028 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight | scheduled | "NCT07790861 (A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07790861)) |
| April 2028 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity | scheduled | "NCT06859268 (A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06859268)) |
| Apr to Jul 2028 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity | scheduled | "NCT06859268 (A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06859268)) |
| April 2028 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Ulcerative Colitis; Obesity or Overweight | scheduled | "NCT06937086 (Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06937086)) |
| Apr to Jul 2028 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Ulcerative Colitis; Obesity or Overweight | scheduled | "NCT06937086 (Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06937086)) |
| April 2028 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Osteoarthritis | scheduled | "NCT07153471 (A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07153471)) |
| Apr to Jul 2028 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Osteoarthritis | scheduled | "NCT07153471 (A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07153471)) |
| April 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Asthma | scheduled | "NCT07219173 (A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219173)) |
| Apr to Jul 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Asthma | scheduled | "NCT07219173 (A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219173)) |
| April 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Alcohol Use Disorder | scheduled | "NCT07219953 (A Study of Brenipatide in Participants With Alcohol Use Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219953)) |
| Apr to Jul 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Alcohol Use Disorder | scheduled | "NCT07219953 (A Study of Brenipatide in Participants With Alcohol Use Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219953)) |
| April 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Alcohol Use Disorder | scheduled | "NCT07219966 (A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219966)) |
| Apr to Jul 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Alcohol Use Disorder | scheduled | "NCT07219966 (A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219966)) |
| May 2028 | [Donanemab primary completion](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease; Dementia; Brain Diseases | scheduled | "NCT05508789 (A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05508789)) |
| May to Aug 2028 | [Donanemab topline data readout](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease; Dementia; Brain Diseases | scheduled | "NCT05508789 (A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05508789)) |
| May 2028 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Crohn's Disease; Obesity or Overweight | scheduled | "NCT06937099 (Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06937099)) |
| May to Aug 2028 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Crohn's Disease; Obesity or Overweight | scheduled | "NCT06937099 (Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06937099)) |
| May 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07759245 (A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07759245)) |
| May to Aug 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07759245 (A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07759245)) |
| May 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Major Depressive Disorder | scheduled | "NCT07928245 (A Study of Brenipatide in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07928245)) |
| May to Aug 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Major Depressive Disorder | scheduled | "NCT07928245 (A Study of Brenipatide in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07928245)) |
| June 2028 | [Jaypirca (pirtobrutinib) primary completion](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT06588478 (A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588478)) |
| Jun to Sep 2028 | [Jaypirca (pirtobrutinib) topline data readout](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT06588478 (A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588478)) |
| June 2028 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Peripheral Arterial Disease | scheduled | "NCT07223593 (Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223593)) |
| Jun to Sep 2028 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Peripheral Arterial Disease | scheduled | "NCT07223593 (Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223593)) |
| June 2028 | [Eloralintide primary completion](https://sec-api.dev/pdufa/eloralintide) | LLY | Overweight; Obesity | scheduled | "NCT07392190 (A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07392190)) |
| Jun to Sep 2028 | [Eloralintide topline data readout](https://sec-api.dev/pdufa/eloralintide) | LLY | Overweight; Obesity | scheduled | "NCT07392190 (A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07392190)) |
| July 2028 | [OLUMIANT® (baricitinib) primary completion](https://sec-api.dev/pdufa/baricitinib) | LLY | Diabetes Mellitus, Type 1 | scheduled | "NCT07222332 (A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222332)) |
| Jul to Oct 2028 | [OLUMIANT® (baricitinib) topline data readout](https://sec-api.dev/pdufa/baricitinib) | LLY | Diabetes Mellitus, Type 1 | scheduled | "NCT07222332 (A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222332)) |
| July 2028 | [Vepugratinib primary completion](https://sec-api.dev/pdufa/vepugratinib) | LLY | Urinary Bladder Neoplasms; Urologic Neoplasms; Receptor, Fibroblast Growth Factor, Type 3 | scheduled | "NCT07827612 (A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07827612)) |
| Jul to Oct 2028 | [Vepugratinib topline data readout](https://sec-api.dev/pdufa/vepugratinib) | LLY | Urinary Bladder Neoplasms; Urologic Neoplasms; Receptor, Fibroblast Growth Factor, Type 3 | scheduled | "NCT07827612 (A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07827612)) |
| August 2028 | [Donanemab primary completion](https://sec-api.dev/pdufa/donanemab) | LLY | Cognitive Dysfunction; Lewy Body Disease; Synucleinopathies | scheduled | "NCT07589595 (A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07589595)) |
| Aug to Nov 2028 | [Donanemab topline data readout](https://sec-api.dev/pdufa/donanemab) | LLY | Cognitive Dysfunction; Lewy Body Disease; Synucleinopathies | scheduled | "NCT07589595 (A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07589595)) |
| October 2028 | [Aavanc80-hotof via akouos delivery device primary completion](https://sec-api.dev/pdufa/aavanc80-hotof-via-akouos-delivery-device) | LLY | Sensorineural Hearing Loss, Bilateral | scheduled | "NCT05821959 (Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05821959)) |
| Oct 2028 to Jan 2029 | [Aavanc80-hotof via akouos delivery device topline data readout](https://sec-api.dev/pdufa/aavanc80-hotof-via-akouos-delivery-device) | LLY | Sensorineural Hearing Loss, Bilateral | scheduled | "NCT05821959 (Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05821959)) |
| October 2028 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight | scheduled | "NCT07357415 (A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07357415)) |
| Oct 2028 to Jan 2029 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight | scheduled | "NCT07357415 (A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07357415)) |
| November 2028 | [Sofetabart mipitecan primary completion](https://sec-api.dev/pdufa/sofetabart-mipitecan) | LLY | Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms | scheduled | "NCT07213804 (A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213804)) |
| Nov 2028 to Feb 2029 | [Sofetabart mipitecan topline data readout](https://sec-api.dev/pdufa/sofetabart-mipitecan) | LLY | Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms | scheduled | "NCT07213804 (A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213804)) |
| November 2028 | [Olomorasib primary completion](https://sec-api.dev/pdufa/olomorasib) | LLY | Colorectal Neoplasms | scheduled | "NCT07814417 (A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07814417)) |
| Nov 2028 to Feb 2029 | [Olomorasib topline data readout](https://sec-api.dev/pdufa/olomorasib) | LLY | Colorectal Neoplasms | scheduled | "NCT07814417 (A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07814417)) |
| December 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Depressive Disorder, Major | scheduled | "NCT07775300 (A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775300)) |
| Dec 2028 to Mar 2029 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Depressive Disorder, Major | scheduled | "NCT07775300 (A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775300)) |
| January 2029 | [Inluriyo™ (imlunestrant) primary completion](https://sec-api.dev/pdufa/imlunestrant) | LLY | Breast Neoplasms | scheduled | "NCT07287098 (A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287098)) |
| Jan to Apr 2029 | [Inluriyo™ (imlunestrant) topline data readout](https://sec-api.dev/pdufa/imlunestrant) | LLY | Breast Neoplasms | scheduled | "NCT07287098 (A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287098)) |
| February 2029 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD) | scheduled | "NCT06383390 (The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06383390)) |
| Feb to May 2029 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD) | scheduled | "NCT06383390 (The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06383390)) |
| March 2029 | [Lepodisiran primary completion](https://sec-api.dev/pdufa/lepodisiran) | LLY | Atherosclerotic Cardiovascular Disease (ASCVD); Elevated Lp(a) | scheduled | "NCT06292013 (A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06292013)) |
| Mar to Jun 2029 | [Lepodisiran topline data readout](https://sec-api.dev/pdufa/lepodisiran) | LLY | Atherosclerotic Cardiovascular Disease (ASCVD); Elevated Lp(a) | scheduled | "NCT06292013 (A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06292013)) |
| April 2029 | [Remternetug primary completion](https://sec-api.dev/pdufa/remternetug) | LLY | Alzheimer's Disease | scheduled | "NCT06653153 (A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06653153)) |
| Apr to Jul 2029 | [Remternetug topline data readout](https://sec-api.dev/pdufa/remternetug) | LLY | Alzheimer's Disease | scheduled | "NCT06653153 (A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06653153)) |
| May 2029 | [Olomorasib primary completion](https://sec-api.dev/pdufa/olomorasib) | LLY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06890598 (Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890598)) |
| May to Aug 2029 | [Olomorasib topline data readout](https://sec-api.dev/pdufa/olomorasib) | LLY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06890598 (Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890598)) |
| May 2029 | [VERZENIO (abemaciclib) primary completion](https://sec-api.dev/pdufa/abemaciclib) | LLY | Breast Neoplasms; Neoplasm Metastasis | scheduled | "NCT07174336 (A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07174336)) |
| May to Aug 2029 | [VERZENIO (abemaciclib) topline data readout](https://sec-api.dev/pdufa/abemaciclib) | LLY | Breast Neoplasms; Neoplasm Metastasis | scheduled | "NCT07174336 (A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07174336)) |
| July 2029 | [Bimagrumab primary completion](https://sec-api.dev/pdufa/bimagrumab) | LLY | Heart Failure, Diastolic; Diastolic Heart Failure; Heart Failure, Normal Ejection Fraction | scheduled | "NCT07920887 (A Study of Bimagrumab in Participants With HFpEF): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07920887)) |
| Jul to Oct 2029 | [Bimagrumab topline data readout](https://sec-api.dev/pdufa/bimagrumab) | LLY | Heart Failure, Diastolic; Diastolic Heart Failure; Heart Failure, Normal Ejection Fraction | scheduled | "NCT07920887 (A Study of Bimagrumab in Participants With HFpEF): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07920887)) |
| August 2029 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Overweight; Prediabetic State; Prehypertension | scheduled | "NCT07794579 (A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794579)) |
| Aug to Nov 2029 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Overweight; Prediabetic State; Prehypertension | scheduled | "NCT07794579 (A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794579)) |
| September 2029 | [Donanemab primary completion](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease; Dementia; Plaque, Amyloid | scheduled | "NCT07602582 (A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07602582)) |
| Sep to Dec 2029 | [Donanemab topline data readout](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease; Dementia; Plaque, Amyloid | scheduled | "NCT07602582 (A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07602582)) |
| October 2029 | [Vepugratinib primary completion](https://sec-api.dev/pdufa/vepugratinib) | LLY | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Neoplasm Metastasis | scheduled | "NCT07218380 (A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218380)) |
| Oct 2029 to Jan 2030 | [Vepugratinib topline data readout](https://sec-api.dev/pdufa/vepugratinib) | LLY | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Neoplasm Metastasis | scheduled | "NCT07218380 (A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218380)) |
| October 2029 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT07881432 (A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881432)) |
| Oct 2029 to Jan 2030 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT07881432 (A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881432)) |
| October 2029 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07881458 (A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881458)) |
| Oct 2029 to Jan 2030 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07881458 (A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881458)) |
| November 2029 | [Eloralintide primary completion](https://sec-api.dev/pdufa/eloralintide) | LLY | Obesity; Overweight; Cardiovascular Diseases | scheduled | "NCT07900633 (A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07900633)) |
| Nov 2029 to Feb 2030 | [Eloralintide topline data readout](https://sec-api.dev/pdufa/eloralintide) | LLY | Obesity; Overweight; Cardiovascular Diseases | scheduled | "NCT07900633 (A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07900633)) |
| December 2029 | [Lepodisiran primary completion](https://sec-api.dev/pdufa/lepodisiran) | LLY | Atherosclerosis; Cardiovascular Diseases; Lipoprotein(a) | scheduled | "NCT07613294 (A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07613294)) |
| Dec 2029 to Mar 2030 | [Lepodisiran topline data readout](https://sec-api.dev/pdufa/lepodisiran) | LLY | Atherosclerosis; Cardiovascular Diseases; Lipoprotein(a) | scheduled | "NCT07613294 (A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07613294)) |
| December 2029 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT07817875 (Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07817875)) |
| Dec 2029 to Mar 2030 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | scheduled | "NCT07817875 (Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07817875)) |
| March 2030 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT07668336 (A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668336)) |
| Mar to Jun 2030 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT07668336 (A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668336)) |
| April 2030 | [Donanemab primary completion](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease | scheduled | "NCT07571161 (Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571161)) |
| Apr to Jul 2030 | [Donanemab topline data readout](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease | scheduled | "NCT07571161 (Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571161)) |
| May 2030 | [Jaypirca (pirtobrutinib) primary completion](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; B-cell Lymphoma | scheduled | "NCT07162181 (Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07162181)) |
| May to Aug 2030 | [Jaypirca (pirtobrutinib) topline data readout](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; B-cell Lymphoma | scheduled | "NCT07162181 (Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07162181)) |
| June 2030 | [Zotemtegrast primary completion](https://sec-api.dev/pdufa/zotemtegrast) | LLY |  | scheduled | "NCT07415044 (LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415044)) |
| Jun to Sep 2030 | [Zotemtegrast topline data readout](https://sec-api.dev/pdufa/zotemtegrast) | LLY |  | scheduled | "NCT07415044 (LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415044)) |
| August 2030 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Metabolic Dysfunction-Associated Steatotic Liver Disease | scheduled | "NCT07165028 (A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07165028)) |
| Aug to Nov 2030 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Metabolic Dysfunction-Associated Steatotic Liver Disease | scheduled | "NCT07165028 (A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07165028)) |

## Drugs

- [Aavanc80-hotof via akouos delivery device](https://sec-api.dev/pdufa/aavanc80-hotof-via-akouos-delivery-device): Sensorineural Hearing Loss, Bilateral
- [VERZENIO (abemaciclib)](https://sec-api.dev/pdufa/abemaciclib): Breast Neoplasms, Glioma
- [OLUMIANT® (baricitinib)](https://sec-api.dev/pdufa/baricitinib): Systemic Juvenile Idiopathic Arthritis, Areata Alopecia, Diabetes Mellitus, Type 1
- [Bimagrumab](https://sec-api.dev/pdufa/bimagrumab): Heart Failure, Diastolic
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide): Opioid Use Disorder, Depressive Disorder, Major, Irritable Bowel Syndrome, Major Depressive Disorder, Bipolar Disorder, Smoking, Pulmonary Disease, Chronic Obstructive, Alcohol Use Disorder, Asthma, Schizophrenia
- [Clazakizumab](https://sec-api.dev/pdufa/clazakizumab): Atherosclerosis
- [Donanemab](https://sec-api.dev/pdufa/donanemab): Cognitive Dysfunction, Alzheimer Disease
- [Kisunla (donanemab-azbt)](https://sec-api.dev/pdufa/donanemab-azbt): To treat Alzheimer’s disease
- [Trulicity (dulaglutide)](https://sec-api.dev/pdufa/dulaglutide): Type 2 Diabetes
- [Cymbalta (duloxetine)](https://sec-api.dev/pdufa/duloxetine): 
- [Eloralintide](https://sec-api.dev/pdufa/eloralintide): Sleep Apnea, Obstructive, Obesity, Overweight, Osteoarthritis
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart): Ulcerative Colitis, Hidradenitis Suppurativa
- [Galcanezumab](https://sec-api.dev/pdufa/galcanezumab): Episodic Migraine, Chronic Migraine
- [Emgality (galcanezumab-gnlm)](https://sec-api.dev/pdufa/galcanezumab-gnlm): 
- [Inluriyo™ (imlunestrant)](https://sec-api.dev/pdufa/imlunestrant): Breast Neoplasms
- [Onswik (insulin efsitora alfa-gobe)](https://sec-api.dev/pdufa/insulin-efsitora-alfa-gobe): 
- [Rezvoglar (insulin glargine-aglr)](https://sec-api.dev/pdufa/insulin-glargine-aglr): 
- [Lyumjev (insulin lispro-aabc)](https://sec-api.dev/pdufa/insulin-lispro-aabc): 
- [Taltz (ixekizumab)](https://sec-api.dev/pdufa/ixekizumab): Psoriatic Arthritis, Psoriasis
- [Reyvow (lasmiditan succinate)](https://sec-api.dev/pdufa/lasmiditan): Migraine
- [Lebrikizumab](https://sec-api.dev/pdufa/lebrikizumab): Atopic Dermatitis, Atopic Hand and Foot Dermatitis
- [Ebglyss (lebrikizumab-lbkz)](https://sec-api.dev/pdufa/lebrikizumab-lbkz): To treat moderate-to-severe atopic dermatitis
- [Lepodisiran](https://sec-api.dev/pdufa/lepodisiran): Atherosclerosis, Atherosclerotic Cardiovascular Disease (ASCVD)
- [Ly3016859 isa](https://sec-api.dev/pdufa/ly3016859-isa): Osteoarthritis, Knee
- [LY3457263](https://sec-api.dev/pdufa/ly3457263): Type 2 Diabetes
- [LY3537021](https://sec-api.dev/pdufa/ly3537021): Nausea
- [LY3541860](https://sec-api.dev/pdufa/ly3541860): Multiple Sclerosis, Rheumatoid Arthritis
- [LY3549492](https://sec-api.dev/pdufa/ly3549492): Obesity, Healthy
- [LY3650150](https://sec-api.dev/pdufa/ly3650150): Perennial Allergic Rhinitis (PAR), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- [LY3848575](https://sec-api.dev/pdufa/ly3848575): Neuropathic Pain
- [LY3871801](https://sec-api.dev/pdufa/ly3871801): Rheumatoid Arthritis
- [LY3938577](https://sec-api.dev/pdufa/ly3938577): Diabetes Mellitus, Type 2
- [LY4005130](https://sec-api.dev/pdufa/ly4005130): Alopecia Areata, Vitiligo
- [LY4065967](https://sec-api.dev/pdufa/ly4065967): Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee
- [LY4086940](https://sec-api.dev/pdufa/ly4086940): Obesity
- [LY4395089](https://sec-api.dev/pdufa/ly4395089): Colitis, Ulcerative, Crohn Disease
- [LY4515100](https://sec-api.dev/pdufa/ly4515100): Acute Pain
- [Macupatide](https://sec-api.dev/pdufa/macupatide): Obesity, Overweight
- [Mazdutide](https://sec-api.dev/pdufa/mazdutide): Alcohol Use Disorder
- [Mazisotine](https://sec-api.dev/pdufa/mazisotine): Diabetic Peripheral Neuropathy
- [Mevidalen](https://sec-api.dev/pdufa/mevidalen): Alzheimer Disease
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab): Ulcerative Colitis, Crohn's Disease
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv): Ulcerative Colitis
- [Omvoh (mirikizumab-mrkz)](https://sec-api.dev/pdufa/mirikizumab-mrkz): To treat ulcerative colitis
- [Lartruvo (olaratumab)](https://sec-api.dev/pdufa/olaratumab): 
- [Olomorasib](https://sec-api.dev/pdufa/olomorasib): Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron): Hypertension, Type 2 Diabetes, Obesity, Urinary Incontinence,Stress, OSA, Overweight, Osteoarthritis, Peripheral Arterial Disease, Diabetes Mellitus, Type 2
- [Alimta (pemetrexed)](https://sec-api.dev/pdufa/pemetrexed): Carcinoma, Non-Small-Cell Lung
- [Jaypirca (pirtobrutinib)](https://sec-api.dev/pdufa/pirtobrutinib): Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell
- [Cyramza (ramucirumab)](https://sec-api.dev/pdufa/ramucirumab): Neoplasms
- [Remternetug](https://sec-api.dev/pdufa/remternetug): Alzheimer's Disease
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide): Overweight or Obesity, Obesity, Diabetes Type 2, Diabetes Mellitus, Type 2, Type 2 Diabetes, Atherosclerotic Cardiovascular Disease (ASCVD)
- [Retevmo (selpercatinib)](https://sec-api.dev/pdufa/selpercatinib): Carcinoma, Non-Small-Cell Lung
- [Sofetabart mipitecan](https://sec-api.dev/pdufa/sofetabart-mipitecan): Ovarian Neoplasms
- [Solbinsiran](https://sec-api.dev/pdufa/solbinsiran): Severe Hypertriglyceridemia
- [Forteo® (teriparatide)](https://sec-api.dev/pdufa/teriparatide): 
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide): Obesity, Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight, Type 2 Diabetes Mellitus, Type 2 Diabetes, Ulcerative Colitis, Crohn's Disease, Type 1 Diabetes
- [Vepugratinib](https://sec-api.dev/pdufa/vepugratinib): Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast): Ulcerative Colitis (UC), Ulcerative Colitis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/lly/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LLY catalysts: ELI LILLY & Co PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/lly/catalysts

```bibtex
@misc{secapidev_companies_lly_catalysts_20261116,
  title        = {LLY catalysts: ELI LILLY & Co PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/lly/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_lly_catalysts_20261116","title":"LLY catalysts: ELI LILLY & Co PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/lly/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
